400 related articles for article (PubMed ID: 29572005)
1. Programmed cell death-ligand 1 (PD-L1) expression is associated with RAS/TP53 mutations in lung adenocarcinoma.
Serra P; Petat A; Maury JM; Thivolet-Bejui F; Chalabreysse L; Barritault M; Ebran N; Milano G; Girard N; Brevet M
Lung Cancer; 2018 Apr; 118():62-68. PubMed ID: 29572005
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.
Cha YJ; Kim HR; Lee CY; Cho BC; Shim HS
Lung Cancer; 2016 Jul; 97():73-80. PubMed ID: 27237031
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements.
Yoneshima Y; Ijichi K; Anai S; Ota K; Otsubo K; Iwama E; Tanaka K; Oda Y; Nakanishi Y; Okamoto I
Lung Cancer; 2018 Apr; 118():36-40. PubMed ID: 29572000
[TBL] [Abstract][Full Text] [Related]
4. Programmed death ligand 1 protein expression is positively correlated with the solid predominant subtype, high MIB-1 labeling index, and p53 expression and negatively correlated with epidermal growth factor receptor mutations in lung adenocarcinoma.
Yanagawa N; Shiono S; Endo M; Ogata SY; Yamada N; Sugimoto R; Osakabe M; Uesugi N; Sugai T
Hum Pathol; 2021 Feb; 108():12-21. PubMed ID: 33159965
[TBL] [Abstract][Full Text] [Related]
5. Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma.
Takada K; Okamoto T; Shoji F; Shimokawa M; Akamine T; Takamori S; Katsura M; Suzuki Y; Fujishita T; Toyokawa G; Morodomi Y; Okano S; Oda Y; Maehara Y
J Thorac Oncol; 2016 Nov; 11(11):1879-1890. PubMed ID: 27346415
[TBL] [Abstract][Full Text] [Related]
6. Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells.
Cruz-Rico G; Avilés-Salas A; Popa-Navarro X; Lara-Mejía L; Catalán R; Sánchez-Reyes R; López-Sánchez D; Cabrera-Miranda L; Aquiles Maldonado-Martínez H; Samtani-Bassarmal S; Arrieta O
Pathol Oncol Res; 2021; 27():597499. PubMed ID: 34257548
[No Abstract] [Full Text] [Related]
7. Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas.
Driver BR; Miller RA; Miller T; Deavers M; Gorman B; Mody D; Ge Y; Barrios R; Bernicker E; Kim M; Cagle PT
Arch Pathol Lab Med; 2017 Nov; 141(11):1529-1532. PubMed ID: 28829153
[TBL] [Abstract][Full Text] [Related]
8. [Consistency of PD-L1 immunohistochemical detection platforms in biopsy samples with advanced lung adenocarcinoma: a multicenter study].
Yuan P; Guo CY; Li Y; Jiang LL; Liu YP; Liu XY; Ying JM
Zhonghua Bing Li Xue Za Zhi; 2018 Nov; 47(11):840-844. PubMed ID: 30423607
[No Abstract] [Full Text] [Related]
9. Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment.
Huynh TG; Morales-Oyarvide V; Campo MJ; Gainor JF; Bozkurtlar E; Uruga H; Zhao L; Gomez-Caraballo M; Hata AN; Mark EJ; Lanuti M; Engelman JA; Mino-Kenudson M
J Thorac Oncol; 2016 Nov; 11(11):1869-1878. PubMed ID: 27568346
[TBL] [Abstract][Full Text] [Related]
10. Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma.
Song Z; Yu X; Cheng G; Zhang Y
J Transl Med; 2016 Jun; 14(1):188. PubMed ID: 27342566
[TBL] [Abstract][Full Text] [Related]
11. Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma.
Yeo MK; Choi SY; Seong IO; Suh KS; Kim JM; Kim KH
Hum Pathol; 2017 Oct; 68():103-111. PubMed ID: 28851662
[TBL] [Abstract][Full Text] [Related]
12. Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1).
Shimoji M; Shimizu S; Sato K; Suda K; Kobayashi Y; Tomizawa K; Takemoto T; Mitsudomi T
Lung Cancer; 2016 Aug; 98():69-75. PubMed ID: 27393509
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of ≥ 50% PD-L1 expression with the SP263 monoclonal antibody in non-small cell lung cancer patients.
Li W; Song P; Guo L; Liu X; Guo C; Ying J; Gao S
Thorac Cancer; 2019 Feb; 10(2):175-182. PubMed ID: 30536734
[TBL] [Abstract][Full Text] [Related]
14. A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project.
Kerr KM; Thunnissen E; Dafni U; Finn SP; Bubendorf L; Soltermann A; Verbeken E; Biernat W; Warth A; Marchetti A; Speel EM; Pokharel S; Quinn AM; Monkhorst K; Navarro A; Madsen LB; Radonic T; Wilson J; De Luca G; Gray SG; Cheney R; Savic S; Martorell M; Muley T; Baas P; Meldgaard P; Blackhall F; Dingemans AM; Dziadziuszko R; Vansteenkiste J; Weder W; Polydoropoulou V; Geiger T; Kammler R; Peters S; Stahel R;
Lung Cancer; 2019 May; 131():95-103. PubMed ID: 31027705
[TBL] [Abstract][Full Text] [Related]
15. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
Rangachari D; VanderLaan PA; Shea M; Le X; Huberman MS; Kobayashi SS; Costa DB
J Thorac Oncol; 2017 May; 12(5):878-883. PubMed ID: 28104537
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer.
Kim H; Kwon HJ; Park SY; Park Y; Park E; Chung JH
PLoS One; 2018; 13(6):e0198634. PubMed ID: 29856861
[TBL] [Abstract][Full Text] [Related]
17. Potential Predictive Value of
Dong ZY; Zhong WZ; Zhang XC; Su J; Xie Z; Liu SY; Tu HY; Chen HJ; Sun YL; Zhou Q; Yang JJ; Yang XN; Lin JX; Yan HH; Zhai HR; Yan LX; Liao RQ; Wu SP; Wu YL
Clin Cancer Res; 2017 Jun; 23(12):3012-3024. PubMed ID: 28039262
[No Abstract] [Full Text] [Related]
18. [Correlation between the Expression of PD-L1 in Pleural Effusion of Lung Adenocarcinoma and the Clinicopathological Features and Molecular Changes].
Ma H; Jia J; Guo H; Zhao H; Wang C; Zhao L; Sun Y; Li W; Zhang Z
Zhongguo Fei Ai Za Zhi; 2020 Mar; 23(3):150-155. PubMed ID: 32209183
[TBL] [Abstract][Full Text] [Related]
19. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
[TBL] [Abstract][Full Text] [Related]
20. Relevance Between Programmed Death Ligand 1 and Radiologic Invasiveness in Pathologic Stage I Lung Adenocarcinoma.
Toyokawa G; Takada K; Okamoto T; Kawanami S; Kozuma Y; Matsubara T; Haratake N; Takamori S; Akamine T; Katsura M; Yamada Y; Shoji F; Baba S; Kamitani T; Oda Y; Honda H; Maehara Y
Ann Thorac Surg; 2017 Jun; 103(6):1750-1757. PubMed ID: 28347537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
